Alpha 201 macro1
Alternative Names: Alpha-201-macro1Latest Information Update: 12 Feb 2024
At a glance
- Originator Candel Therapeutics
- Class Antineoplastics; Gene therapies; Immunotherapies; Oncolytic viruses
- Mechanism of Action CD47 antigen inhibitors; Cell death stimulants; Immunologic cytotoxicity; SIRPA protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Haematological malignancies; Solid tumours
Most Recent Events
- 05 Feb 2024 Pharmacodynamics data from a preclinical study in solid tumours released by Candel Therapeutics
- 04 Nov 2023 Preclinical trials in Haematological malignancies in USA (Parenteral) prior to December 2023
- 04 Nov 2023 Pharmacodynamics data from a preclinical trial in Solid and Hematological malignancies released by Candel Therapeutics